


Improving the quality of judgement in cancer therapeutics development

April 1, 2016 to March 31, 2019

Highlights

- Provide cancer researchers with critical tools to improve decision-making surrounding research, development and study design;
- Establish the feasibility of improving researcher judgement in drug development
- Measure the value of improving researcher judgement, minimizing patient burden and maximizing the efficient use of public investments in drug development.



About the project


Therapeutic cancer drug development requires good judgment about product safety, efficacy and the feasibility of trials. However, we know next to nothing about the quality of this judgment. What we do know is that most cancer therapies put into development either fail to show benefit or show unexpected toxicity; that research often takes longer than expected; and that many trials fail to recruit enough patients. We also know that experts in medicine, science and innovation are prone to ignoring conflicting evidence, and overestimating the benefits and feasibility of their projects. Consequently, there is good reason to suspect that expert judgment in the development of cancer therapies could be improved.

Through three subprojects, Dr. Kimmelman's team will directly measure and refine the quality of judgements from a wide array of experts at various critical times in the development process of several types of cancer biotherapeutics. This data will provide BioCanRx with the ability to interpret systematic reviews, and apply better scientific judgement in relation to projects within the network.

Key investigator

Dr. Jonathan
Kimmelman
McGill

Project investigators



Alberta
University of Alberta
Scientific investigator
 Dr. Christopher McCabe

Toronto
Princess Margaret Cancer Centre, University Health Network
Collaborators
 Dr. Marcus Butler
 Dr. Christopher Paige

Ottawa
The Ottawa Hospital, University of Ottawa
Scientific investigators
 Dr. Dean Fergusson
 Dr. Manoj Lalu
Collaborators
 Dr. Harry Atkins
 Dr. John Bell
Trainee
 Dr. Marc Avey

Montreal
McGill University
Scientific investigator
 Dr. Jonathan Kimmelman
Trainee
 Daniel Benjamin
 Adelaide Doussau de Bazignan

Kingston
Canadian Clinical Trials Group
Collaborator
 Dr. Janet Dancey

BioCanRx
\$538,846
 approved on
 January 5, 2016

Partner contributions
 Canadian Clinical Trials Group
\$15,000 in kind for technical expertise

April 1, 2016
 Project starts

April 1, 2016 to September 30, 2017
Subproject 2
 Literature searches, extraction and analysis, randomization, training and forecast collection, write up of systematic reviews.

October 1, 2016 to December 31, 2018
Subproject 1
 Feedback and training, analysis

April 1, 2017 to March 31, 2018
Subproject 3
 Model creation, using forecast analysis

October 1, 2017 to March 31, 2019
 Final analysis and report to BioCanRx

The power to kill cancer lies within us.
 Let's tell our bodies how.

